Does treatment reduce corticosteroid dependency in asthma?

Researchers examined the efficacy of the human monoclonal antibody tezepelumab in minimizing oral corticosteroid use in patients with corticosteroid-dependent asthma.

In the Phase 3 SUNRISE trial, published in The Lancet Respiratory Medicine, the researchers randomly assigned more than 120 participants aged 18 to 80 years who had physician-diagnosed asthma and were treated with medium or high doses of oral corticosteroids to receive either 210 milligrams of subcutaneous tezepelumab or placebo every four weeks for a period of 28 weeks.

Although the study was terminated early as a result of issues with study completion among more than 25% of the participants, the researchers found that the participants who did complete the study achieved greater oral corticosteroid use with tezepelumab compared with placebo. In addition, a lower percentage of patients who received tezepelumab experienced at least one asthma exacerbation and adverse or serious adverse events compared with those who received placebo.

The findings suggested that the use of tezepelumab may help reduce oral corticosteroid dependency and maintain asthma control.

Read more: The Lancet Respiratory Medicine

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.